| All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china | |
| Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng | |
| 2019 | |
| 卷号 | 70 |
| DOI | 10.1016/S0618-8278(19)30467-0 |
| 收录类别 | SCIE |
| 会议录 | JOURNAL OF HEPATOLOGY
 |
| 语种 | 英语 |
| URL标识 | 查看原文 |
| ISSN号 | 0168-8278 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4234283 |
| 专题 | 武汉大学 |
| 推荐引用方式 GB/T 7714 | Wei, Lai,Xu, Xiaoyuan,Guan, Yujuan,et al. All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china[C]. 见:. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论